Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial

NCT06220032 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT06220032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 3
Overall status
Recruiting
Start date
August 15, 2024
Completion date
December 15, 2028
Enrollment
324 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma